Editorial Commentary: Understanding BCG is the key to improving it

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 481-482

  McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

BCG; efficacy; vaccine

Indexed keywords

BCG VACCINE;

ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIAL STRAIN; BIRTH; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LUNG TUBERCULOSIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NOTE; PRIORITY JOURNAL; TUBERCULIN TEST; TUBERCULOSIS; IMMUNOLOGY; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MILIARY; TUBERCULOSIS, PULMONARY;

BCG VACCINE; HUMANS; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MILIARY; TUBERCULOSIS, PULMONARY;

EID: 84893284745     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit793     Document Type: Note

References (8)

1. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702.
2. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012; 92(suppl 1):S6-13.
3. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-8.
4. Black GF, Weir RE, Floyd S, et al. BCGinduced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359:1393-401.
5. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70:672-8.
6. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977; 2:293-5.
7. Burl S, Adetifa UJ, Cox M, et al. Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 2010; 185: 2620-8.
8. Checkley AM, Wyllie DH, Scriba TJ, et al. Identification of antigens specific to nontuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses. PLoS One 2011; 6:e26434.